CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 37097465.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0490 and PMC identifier 10330271.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a retrospective analysis of patients with unresectable melanoma, higher pretreatment tissue densities of CD16+ macrophages were associated with clinical benefit from combined CTLA-4 and PD-1 blockade. With further validation, this biomarker could serve as a tool in selecting between immune checkpoint inhibitor regimens. See related article by Lee et al., p. 2513.
Medical subject headings
- Melanoma